Risky Science: Is Anybody Watching The Experimental AIDS Mouse?

When research is mobilized around combating a virulent infectious agent, risk-taking is inevitable. That has been true in the pursuit of a polio vaccine and a cure for smallpox, in the study of cancer-causing viruses, and most recently, in AIDS research. While the responsible course of action is to limit as much as possible the risks to investigators and laboratory technicians, those goals can only be accomplished within certain limits. Infectious organisms are opportunistic, always seeking n

Written bySheldon Krimsky
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

While the responsible course of action is to limit as much as possible the risks to investigators and laboratory technicians, those goals can only be accomplished within certain limits. Infectious organisms are opportunistic, always seeking new hosts and hew pathways to old hosts. Even under the highest biological containment conditions, laboratory workers have been infected with their experimental agents. While the risks of working with laboratory pathogens cannot be eliminated, strict guidelines, health monitoring, improved facilities, and constant vigilance have proven effective in reducing the incidence of laboratory infections.

Beyond the risk of laboratory induced infections, working with some organisms poses a risk that the agents will be released into the environment, possibly in new forms or through new routes of infection. Thus, there are ethical questions raised when experimenting with highly infectious and virulent agents. Is it appropriate to carry out experiments that may increase the host range of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies